FDA Licenses 15 New Blood Typing Tests - Tests Help Ensure Safe Blood Transfusions For Patients

September 18, 2007 – 12:03 pm | posted in Blood / Hematology

The U.S. Food and Drug Administration licensed 15 new blood typing tests that were previously unavailable in the United States.

These tests, known as blood grouping reagents, are used to determine the blood type of blood donors, an essential step in ensuring safe blood transfusion for patients. If mismatched blood is administered to a patient, it may cause a serious and potentially fatal reaction. To prevent such problems, people must receive compatible blood based on the results of blood typing tests.

The newly approved ALBAclone Blood Grouping Reagents include the common ABO and Rh tests, plus tests for rare blood types. The reagents are monoclonal antibodies, highly specific antibodies that ensure product uniformity and availability.

“The licensing of these reagents will provide more choice for blood establishments and transfusion services and may facilitate testing for rare blood groups,” said Jesse L. Goodman, M.D., M.P.H., director of FDA’s Center for Biologics Evaluation and Research. “Licensure of these additional blood grouping reagents will help ensure a more stable supply of these tests, especially important in the event of a product shortage.”

The reagents are manufactured by Alba Bioscience, Inc. of Durham, N.C.

ShareThis

Also Read

  • American Red Cross Blood Services Supports The Blood Needs Of Southern California
  • New Online Service Explains Pathology Tests, Australia
  • New Test Is Immediately Useful In Diagnosing Heart Failure
  • Give Blood Before You Go Away For The Long Weekend - Save Up To Three Lives, Canada
  • Blood For The Troops Joint Statement, USA
  • Blood Transfusions Raise Heart Patients’ Infection And Death Risk — Especially Women
  • New Findings May Change The Way Heart Disease Is Detected And Treated In Women, From The ‘Harvard Women’s Health Watch’
  • Upper GI endoscopy, Stomach polyp, pathology reports abnormal cells?
  • Long-Term Use Of Revlimid(R) In A Wide Range Of Myelodysplastic Syndromes (MDS) Presented At The 48th Annual American Society Of Hematology Meeting
  • Transfusion Expert Urges Wider Use Of Filtered Blood

    • You must be logged in to post a comment.